Clinical review report : indication: treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. Certolizumab pegol (Cimzia) (UCB Canada Inc.) / Canadian Agency for Drugs and Technologies in Health.

Format:

Book

Author/Creator:

Canadian Agency for Drugs and Technologies in Health, author, issuing body.

Series:

Common drug review clinical review report.

Common drug review clinical review report

Language:

English

Subjects (All):

Outcome assessment (Medical care).

Physical Description:

1 online resource (120 pages) : illustrations.

Edition:

Final (with redactions).

Place of Publication:

Ottawa (ON) : CADTH, 2020.

Summary:

The objective of this report was to perform a systematic review of the beneficial and harmful effects of Certolizumab pegol 400 mg and 200 mg every two weeks administered as an subcutaneous injection for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.

Contents:

Abbreviations

Executive Summary

Introduction

Results and Interpretation

Conclusions

Disease Prevalence and Incidence

Standards of Therapy

Drug

Objectives and Methods

Objectives

Methods

Results

Findings From the Literature

Included Studies

Exposure to Study Treatments

Critical Appraisal

Efficacy

Harms

Discussion

Summary of Available Evidence

Interpretation of Results

Appendix 1. Patient Input Summary

Appendix 2. Literature Search Strategy

Appendix 3. Excluded Studies

Appendix 4. Detailed Outcome Data

Appendix 5. Validity of Outcome Measures

Appendix 6. Summary of Other Studies

Appendix 7. Summary of Indirect Comparisons

References.

Notes:

Includes bibliographical referneces.

Description based on publisher supplied metadata and other sources.